Matthew J. Hart, Ph.D.
Rank: Associate Professor/Research
Department: Biochemistry & Structural Biology
Location: Greehey CCRI
Matthew J. Hart, Ph.D., joined the Greehey Children’s Cancer Research Institute (Greehey CCRI) as Director of the Greehey CCRI RNAi/CRISPR High Throughput Screening Facility in November 2016. Dr. Hart is also an Associate Professor/Research in the Department of Biochemistry at UT Health San Antonio. Dr. Hart also serves as the Director of the High Throughput Screening Facility (HTSF), one of two core facilities that comprise the Center for Innovative Drug Discovery (CIDD) at UT Health. Dr. Hart’s focus as leader of the Greehey CCRI RNAi/CRISPR High Throughput Screening Facility is to use genetic tools to identify targets and signaling events that play a role in pediatric cancer.
Dr. Hart received his doctoral degree from Cornell University and did his postdoctoral training at Onyx Pharmaceuticals. His work identified CDC42 as a regulator of cell growth control, established the role of CDC42 in the regulation of EGFR and Dbl, the involvement of p115-RhoGEF in heterotrimeric G-protein signaling, and identified β-TrCP as a regulator of ß-catenin signaling. His current work builds on 21 years of experience in basic biomedical research and drug discovery both in pharmaceutical and academic settings, where he led teams in HTS drug discovery targeting key mechanisms of cancer, vascular inflammation, and neurodegenerative diseases.Dr. Hart's UT Health San Antonio, Faculty Profile
Daifeng Jiang, Ph.D.
- Aging Cell: mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging November 6, 2019
- Bioorganic & Medicinal Chemistry: Synthesis and SAR of novel capsazepine analogs with significant anti-cancer effects in multiple cancer types June 1, 2019
- Journal of Oral Pathology & Medicine: The novel capsazepine analog, CIDD‐99, significantly inhibits oral squamous cell carcinoma in vivo through a TRPV1‐independent induction of ER stress, mitochondrial dysfunction, and apoptosis February 3, 2019